Edition:
India

MabVax Therapeutics Holdings Inc (MBVX.OQ)

MBVX.OQ on NASDAQ Stock Exchange Capital Market

0.81USD
2:29am IST
Change (% chg)

$-0.04 (-4.71%)
Prev Close
$0.85
Open
$0.86
Day's High
$0.89
Day's Low
$0.81
Volume
17,312
Avg. Vol
69,728
52-wk High
$3.88
52-wk Low
$0.43

Latest Key Developments (Source: Significant Developments)

MabVax Completes Enrollment In Initial Cohort Of Its Cancer Drug
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - MabVax Therapeutics Holdings Inc ::MABVAX THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT AND DOSING IN INITIAL COHORT OF MVT-1075 RADIOIMMUNOTHERAPY PHASE 1 TRIAL FOR THE TREATMENT OF PANCREATIC, COLON AND LUNG CANCERS.MABVAX THERAPEUTICS HOLDINGS INC - PLANS TO REPORT INTERIM RESULTS FROM STUDY EARLY IN Q1 OF 2018 AND CONTINUE DOSE ESCALATION PHASE OF PROGRAM.  Full Article

MabVax Therapeutics files for resale of 9.7 mln shares‍​
Thursday, 26 Oct 2017 

Oct 25 (Reuters) - MabVax Therapeutics Holdings Inc : :MabVax Therapeutics Holdings Inc - files for resale of 9.7 million shares of common stock of co by certain stockholders ‍​.  Full Article

MabVax Therapeutics files for resale of up to 6.97 mln shares of co's common stock‍​
Friday, 20 Oct 2017 

Oct 20 (Reuters) - MabVax Therapeutics Holdings Inc :MabVax Therapeutics Holdings Inc files for resale of up to 6.97 million shares of co's common stock‍​ by the selling stockholders - SEC filing‍​.  Full Article

Mabvax Therapeutics starts patient enrollment in phase 1 trial for cancer drug MVT-1075
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Mabvax Therapeutics Holdings Inc :Mabvax Therapeutics initiates patient enrollment in a phase 1 trial for MVT-1075, a new radioimmunotherapy treatment for advanced pancreatic, colon and lung cancers.Mabvax Therapeutics Holdings Inc - ‍Plans to announce topline interim results before year end from study​.  Full Article

MabVax stockholders approve remaining proposal at stockholders meeting
Saturday, 7 Oct 2017 

Oct 6 (Reuters) - MabVax Therapeutics Holdings Inc :MabVax Therapeutics Holdings - ‍resolution approved to implement, if necessary a reverse stock split of company's issued and outstanding common stock​.MabVax Therapeutics Holdings Inc - ‍ implementation of reverse stock split stock by a ratio of not less than 1 -for-2 and not more than 1 -for-20.  Full Article

MabVax Therapeutics expands patient enrollment in phase I trial for treatment of pancreatic cancer
Tuesday, 7 Jun 2016 

Mabvax Therapeutics Holdings Inc :MabVax therapeutics expands patient enrollment in phase I trial for treatment of pancreatic cancer to Memorial Sloan Kettering Cancer Center.  Full Article

BRIEF-MabVax Completes Enrollment In Initial Cohort Of Its Cancer Drug

* MABVAX THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT AND DOSING IN INITIAL COHORT OF MVT-1075 RADIOIMMUNOTHERAPY PHASE 1 TRIAL FOR THE TREATMENT OF PANCREATIC, COLON AND LUNG CANCERS